NovAliX results from the merger in 2009 of Novalyst Discovery, a chemistry services company, and AliX, a structural biology company.
NovAliX is a private company combining structural biology, medicinal chemistry and an in-house developed screening technology to conduct integrated drug discovery programs.
NovAliX provides target-driven solutions for drug discovery offering access to diverse and relevant approaches such as natural product-based drug discovery and fragment-based drug design (FBDD).
The fragment selection process (FAMASS) is powered by an innovative mass spectrometry screening technology delivering high-content information on compound-protein interactions (binding evidence, stoichiometry, reversibility, specificity, binding affinity...). This biophysical method is also advantageously used for library hit validation and hit or lead analog ranking.
In addition, through its integrated platform in chemistry and biology, NovAliX provides various single services in organic synthesis and protein crystallography.
As of today, NovAliX operates in Strasbourg with 60 scientists in state-of-the-art facilities (1600 m2) equipped to carry out multidisciplinary research.
Press Releases :
For More Informations :
